The U.S. Food and Drug Administration approved Agios Pharmaceuticals Inc.’s oral PK activator Pyrukynd (mitapivat) as the first approved disease-modifying therapy for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
https://www.pharmalive.com/wp-content/uploads/2022/02/PYRUKYND-Logo.png331600GlobeNewswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngGlobeNewswire2022-02-17 17:05:332022-02-18 14:38:27FDA Approves Agios Pharmaceuticals’ Pyrukynd as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency